Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: a pilot endoscopic study in healthy male subjects

Abstract
Background : Lumiracoxib (Prexige®) is a cyclooxygenase‐2 (COX‐2) selective inhibitor. Aim : To compare the gastroduodenal tolerability of lumiracoxib with placebo and naproxen in a randomized, paral...